Non-Alcoholic Steatohepatitis (NASH) Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,UK,China - Size and Forecast 2023-2027

Published: Oct 2023 Pages: 146 SKU: IRTNTR76150

Non-Alcoholic Steatohepatitis (NASH) Market Size 2023-2027

The global non-alcoholic steatohepatitis (NASH) market size is estimated to grow by USD 11.22 billion at a CAGR of 40.05% between 2022 and 2027. 

With increasing awareness of the link between obesity, metabolic syndrome, and non-alcoholic steatohepatitis, healthcare providers are more likely to screen and diagnose non-alcoholic steatosis patients. Higher diagnosis rates are driving demand for alcohol-free diagnostic tools and services related to steatohepatitis. Furthermore, the complex interplay between obesity metabolic syndrome and highlights the importance of a multidisciplinary approach involving hepatologists, endocrinologists, and endocrinologists. , nutritionists, and other professionals. This collaborative effort advances research and patient care. Hence, due to the increasing prevalence of obesity and metabolic syndrome, the market will witness positive growth during the forecast period.

What will be the size of the Market During the Forecast Period?

To learn more about this market report, Request Free Sample

Market Segmentation

The market confronts the challenge of addressing liver disease aggravated by factors like chopped strand, silica sand, and soda ash in various industries. With roots possibly linked to limestone exposure, this ailment affects millions worldwide. Its impact mirrors the complexity of pipes and body panels, requiring comprehensive solutions akin to wheelhouse assemblies and front fascia repair. Innovative treatments aim to reinforce the liver's fabric, acting as a protective battery box amidst the storm of liver inflammation.

Technavio has segmented the market into Distribution Channel, Application, and Geography. 

  • The distribution channel includes offline and online
  • The application includes diagnosis and treatment
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021 besides analyzing the current market scenario.

By Distribution Channel

The market share growth by the offline segment will be significant during the forecast period. Offline distribution can play a role in disseminating educational material and growing awareness about non-alcoholic Steatohepatitis. Clinics, healthcare provider offices, and community health centers can distribute leaflets, brochures, and other resources to patients to improve their understanding of non-alcoholic steatohepatitis, its risks, and how it works.

Get a glance at the market contribution of various segments View a PDF Sample

The offline segment was valued at USD 632.74 million in 2017. Offline delivery includes scheduling and performing these appointments in healthcare settings, allowing healthcare providers to assess disease progression and make necessary adjustments for a treatment plan. Offline distribution channels can facilitate interaction between patients and healthcare providers, allowing for personalized advice and support in making these changes. Therefore, factors such as diagnosis, appointment booking, and support are needed for the treatment of non-alcoholic Steatohepatitis, which will drive the growth of the offline segment in the non-alcoholic steatohepatitis (NASH) market during the forecast period. 

By Application

Non-alcoholic steatohepatitis has various applications in the diagnosis and management of the disease. Diagnosis includes blood tests, imaging techniques, assessment of fibrosis, and liver biopsy. Accurate diagnosis of nonalcoholic steatohepatitis allows healthcare providers to develop personalized treatment plans and track disease progression over time. The diagnosis of nonalcoholic steatohepatitis is an integral part of larger efforts to control and treat the disease. Advances in diagnostic techniques and tools are contributing to early detection, improved patient outcomes, and overall management of nonalcoholic steatohepatitis. Hence, these reasons will drive the growth of the diagnostic segment, which will boost the growth of the market during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Non-alcoholic steatohepatitis is a growing health problem in North America due to factors such as obesity, type 2 diabetes, and a sedentary lifestyle. Diagnostic methods, including blood tests, imaging technology, and noninvasive assessment of cirrhosis, are widely available and accessible in the US and Canada.

Moreover, North America has a good healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories, that support the diagnosis and management of non-alcoholic steatohepatitis. Healthcare providers in the region have access to cutting-edge medical technologies and expertise that enable non-alcoholic Steatohepatitis diagnosis and comprehensive patient care, which will drive the growth of the non-alcoholic Steatohepatitis diagnosis non-alcoholic steatohepatitis market in the region during the forecast period. 

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:

Zydus Lifesciences Ltd.: The company offers non alcoholic steatohepatitis or NASH, such as ELF blood test to detect NASH in patients.

  • AstraZeneca Plc
  • BioPredictive S.A.S
  • Cirius Therapeutics
  • Enzo Biochem Inc.
  • GENFIT SA
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Inventiva S.A.
  • Madrigal Pharmaceuticals Inc.
  • Novo Nordisk AS
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • Intercept Pharmaceuticals Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market witnesses significant strides in addressing liver ailments involving waist circumference, body mass index, and triglycerides as key diagnostic markers. Companies like Akero Therapeutics and Boehringer Ingelheim spearhead research into groundbreaking antidiabetes agents and bone morphogenetic medication for NASH treatment. This robust pipeline of therapies aims to tackle weight management challenges, with players like Phenex Pharmaceuticals driving innovation. Clinicalgov data underscores the pressing need, given rising healthcare expenditure linked to conditions like insulin resistance and associated symptoms such as jaundice, itchy skin, and enlarged liver. Cutting-edge diagnosis techniques, from ultrasound to liver transplant, promise enhanced outcomes for patients. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends and challenges. 

Significant Market Trends

Rising patient engagement and education is the primary trend in the market. Patient education and engagement efforts are helping to raise awareness of non-alcoholic Steatohepatitis in the general community and those at risk. A better understanding of the risk factors, symptoms, and impacts of nonalcoholic steatohepatitis will encourage earlier diagnosis and intervention. Patient education emphasizes the importance of lifestyle changes, such as weight loss, healthy eating, and regular physical activity in managing non-alcoholic steatohepatitis.

Furthermore, attached patients are more likely to accept and maintain these changes, leading to better disease control. Informed patients may be willing to participate in clinical trials of experimental alcohol-free treatments for steatohepatitis. Patient involvement initiatives promote a sense of community and support among people living with non-alcoholic Steatohepatitis. Therefore, increasing patient participation and education will propel the growth of the target market during the forecast period. 

Major Market Challenges

The lack of approved therapies is a challenge that affects the growth of the market. The lack of approved treatments for non-alcoholic steatohepatitis complicates the design and conduct of clinical trials. Developing successful trials requires identifying meaningful endpoints and demonstrating the efficacy and safety of potential treatments without establishing standards. Patients with nonalcoholic steatohepatitis may not have access to targeted treatments that can help them control the disease.

Moreover, the absence of approved therapies motivates researchers and pharmaceutical companies to innovate in clinical trial design, endpoints, and strategies to demonstrate the effectiveness of investigational drugs. Thus, the absence of approved therapies is a significant challenge that impedes the growth of the market during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments.

  • Distribution Channel Outlook 
    • Offline
    • Online
  • Application Outlook 
    • Diagnosis
    • Treatment
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India 
    • Rest of the World 
      • Australia 
      • Argentina
      • Brazil 

Market Analyst Overview:

Steatohepatitis, characterized by nonalcoholic fatty liver damage, poses significant health risks such as fatigue, weakness, and abdominal discomfort. Promising developments in treatment include drugs like cilofexor and Lanifibranor, both panPPAR agonists, under development by AbbVie. These drugs target symptoms like fluid accumulation and pain, aiming to improve liver function and alleviate symptoms associated with the disease. Lifestyle modifications play a crucial role alongside medication, with a focus on addressing genetic predispositions and promoting overall wellbeing. Transient elastography aids in monitoring disease progression, offering insights into blood pressure regulation and the risk of cardiovascular diseases and cancer. These advancements signify a shift towards targeted therapies addressing the root cause of the disease for improved patient outcomes and increased lifespan.

Market Scope

Report Coverage

Details

Page number

146

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 40.05%

Market growth 2023-2027

USD 11.22 billion

Market structure

Concentrated

YoY growth 2022-2023(%)

37.32

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc., GENFIT SA, Gilead Sciences Inc., GlaxoSmithKline Plc, Inventiva S.A., Madrigal Pharmaceuticals Inc., Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG, Zydus Lifesciences Ltd., and Intercept Pharmaceuticals Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global non-alcoholic steatohepatitis market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global non-alcoholic steatohepatitis market 2017 - 2021 ($ million)
    • 4.2 Distribution Channel Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)
    • 4.3 Application Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Offline - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%)
    • 6.4 Online - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Distribution Channel
      • Exhibit 42: Market opportunity by Distribution Channel ($ million)
      • Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)

    7 Market Segmentation by Application

    • 7.1 Market segments
      • Exhibit 44: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 45: Data Table on Application - Market share 2022-2027 (%)
    • 7.2 Comparison by Application
      • Exhibit 46: Chart on Comparison by Application
      • Exhibit 47: Data Table on Comparison by Application
    • 7.3 Diagnosis - Market size and forecast 2022-2027
      • Exhibit 48: Chart on Diagnosis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Data Table on Diagnosis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 50: Chart on Diagnosis - Year-over-year growth 2022-2027 (%)
      • Exhibit 51: Data Table on Diagnosis - Year-over-year growth 2022-2027 (%)
    • 7.4 Treatment - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Treatment - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on Treatment - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on Treatment - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Treatment - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Application
      • Exhibit 56: Market opportunity by Application ($ million)
      • Exhibit 57: Data Table on Market opportunity by Application ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 59: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 60: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 61: Chart on Geographic comparison
      • Exhibit 62: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 Canada - Market size and forecast 2022-2027
      • Exhibit 87: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 99: Market opportunity by geography ($ million)
      • Exhibit 100: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 101: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 103: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 104: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 105: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 106: Matrix on vendor position and classification
            • 12.3 AstraZeneca Plc
              • Exhibit 107: AstraZeneca Plc - Overview
              • Exhibit 108: AstraZeneca Plc - Product / Service
              • Exhibit 109: AstraZeneca Plc - Key news
              • Exhibit 110: AstraZeneca Plc - Key offerings
            • 12.4 BioPredictive S.A.S
              • Exhibit 111: BioPredictive S.A.S - Overview
              • Exhibit 112: BioPredictive S.A.S - Product / Service
              • Exhibit 113: BioPredictive S.A.S - Key offerings
            • 12.5 Cirius Therapeutics
              • Exhibit 114: Cirius Therapeutics - Overview
              • Exhibit 115: Cirius Therapeutics - Product / Service
              • Exhibit 116: Cirius Therapeutics - Key offerings
            • 12.6 Enzo Biochem Inc.
              • Exhibit 117: Enzo Biochem Inc. - Overview
              • Exhibit 118: Enzo Biochem Inc. - Product / Service
              • Exhibit 119: Enzo Biochem Inc. - Key offerings
            • 12.7 GENFIT SA
              • Exhibit 120: GENFIT SA - Overview
              • Exhibit 121: GENFIT SA - Product / Service
              • Exhibit 122: GENFIT SA - Key offerings
            • 12.8 Gilead Sciences Inc.
              • Exhibit 123: Gilead Sciences Inc. - Overview
              • Exhibit 124: Gilead Sciences Inc. - Product / Service
              • Exhibit 125: Gilead Sciences Inc. - Key news
              • Exhibit 126: Gilead Sciences Inc. - Key offerings
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 127: GlaxoSmithKline Plc - Overview
              • Exhibit 128: GlaxoSmithKline Plc - Business segments
              • Exhibit 129: GlaxoSmithKline Plc - Key news
              • Exhibit 130: GlaxoSmithKline Plc - Key offerings
              • Exhibit 131: GlaxoSmithKline Plc - Segment focus
            • 12.10 Intercept Pharmaceuticals Inc.
              • Exhibit 132: Intercept Pharmaceuticals Inc. - Overview
              • Exhibit 133: Intercept Pharmaceuticals Inc. - Product / Service
              • Exhibit 134: Intercept Pharmaceuticals Inc. - Key offerings
            • 12.11 Inventiva S.A.
              • Exhibit 135: Inventiva S.A. - Overview
              • Exhibit 136: Inventiva S.A. - Product / Service
              • Exhibit 137: Inventiva S.A. - Key offerings
            • 12.12 Madrigal Pharmaceuticals Inc.
              • Exhibit 138: Madrigal Pharmaceuticals Inc. - Overview
              • Exhibit 139: Madrigal Pharmaceuticals Inc. - Product / Service
              • Exhibit 140: Madrigal Pharmaceuticals Inc. - Key offerings
            • 12.13 Novo Nordisk AS
              • Exhibit 141: Novo Nordisk AS - Overview
              • Exhibit 142: Novo Nordisk AS - Business segments
              • Exhibit 143: Novo Nordisk AS - Key offerings
              • Exhibit 144: Novo Nordisk AS - Segment focus
            • 12.14 Prometheus Laboratories
              • Exhibit 145: Prometheus Laboratories - Overview
              • Exhibit 146: Prometheus Laboratories - Product / Service
              • Exhibit 147: Prometheus Laboratories - Key offerings
            • 12.15 Siemens Healthineers AG
              • Exhibit 148: Siemens Healthineers AG - Overview
              • Exhibit 149: Siemens Healthineers AG - Business segments
              • Exhibit 150: Siemens Healthineers AG - Key news
              • Exhibit 151: Siemens Healthineers AG - Key offerings
              • Exhibit 152: Siemens Healthineers AG - Segment focus
            • 12.16 Zydus Lifesciences Ltd.
              • Exhibit 153: Zydus Lifesciences Ltd. - Overview
              • Exhibit 154: Zydus Lifesciences Ltd. - Business segments
              • Exhibit 155: Zydus Lifesciences Ltd. - Key offerings
              • Exhibit 156: Zydus Lifesciences Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 157: Inclusions checklist
                • Exhibit 158: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 159: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 160: Research methodology
                • Exhibit 161: Validation techniques employed for market sizing
                • Exhibit 162: Information sources
              • 13.5 List of abbreviations
                • Exhibit 163: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              non-alcoholic steatohepatitis market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis